GOOD

The World’s First Malaria Vaccine Is Almost Here, and Will Be Entirely Not-For-Profit

Makers of the “Mosquirix” inoculations promise that any money earned will go solely to making the drug even more effective.

image via (cc) flickr user john tann

An estimated two hundred million people are infected with the malaria parasite annually. Hundreds of thousands of those infected are eventually killed by the disease, making its mosquito carriers the deadliest animals on earth. It is disproportionately fatal to children, and has long been the scourge of medics and health care workers, as well as economists, who estimate the total costs associated with the ongoing fight against the disease to be in the billions.


Thankfully, its days may soon be numbered.

This past week, pharmaceutical company GlaxoSmithKline announced that their experimental vaccine Mosquirix (also known as RTS,S) has been green-lit by the European Medicines Agency, thereby clearing a major hurdle on the drug’s way of being put into use. GSK claims theirs is the first malaria vaccine to have ever reached this milestone. And while Mosquirix still faces World Health Organization approval before it can be applied across infected regions, the drug is already being discussed as a monumental achievement in the fight against a devastating disease. Speaking with Reuters, GSK scientist Joe Cohen did not mince words: “I have absolutely no reservations in terms of rolling this vaccine out. Why? Because the efficacy, when translated into cases averted and deaths averted, is just tremendous. It will have an enormously significant public health impact.”

Mosquirix is the product of decades of research done in partnership between GSK and the PATH Malaria Vaccine Initiative, with funding provided in part by the Bill and Melinda Gates foundation, reports the BBC. The drug is designed specifically to fight malaria’s parasitic infection in children. Per a release from GSK, the drug was shown to have reduced cases of the disease by anywhere from 25 to over 50 percent, depending on the age of the child at the time of their first injection and subsequent booster shots.

image via (cc) flickr user usarmyafrica

Perhaps just as exciting as the prospect of finally having an inoculative method to prevent, and not just simply treat, malaria is GSK’s pledge that Mosquirix will be entirely non-profit. Instead, the injections will be priced at production cost plus a small mark-up, which will be used to fund research toward more effective iterations of the drug. Sources for Reuters predict this will likely cost in the neighborhood of $5 per injection, in a series of four.

Next, the drug’s makers must submit a series proposals to the World Health Organization. Should the WHO approve the treatment, the door would then be open for GSK to approach individual countries in regards to incorporating the vaccine into their malaria treatment programs. Explains GSK CEO Sir Andrew Witty:

Today’s scientific opinion represents a further important step towards making available for young children the world's first malaria vaccine. While RTS,S on its own is not the complete answer to malaria, its use alongside those interventions currently available such as bed nets and insecticides, would provide a very meaningful contribution to controlling the impact of malaria on children in those African communities that need it the most. The work doesn’t stop here and GSK remains committed to investing in R&D for malaria vaccines and treatments to find more ways to tackle this devastating disease.

So while a fully effective vaccine is still likely a ways away, today we are closer than ever to finally curbing the spread of malaria, once and for all.

****UPDATE***

An earlier version of this post mistakenly labled Malaria as a virus, and not a parasite.

[via goodnewsnetwork]

Articles
via International Monetary Fund / Flickr and Streetsblog Denver / Flickr

Seventeen-year-old Swedish climate activist Greta Thunberg made a dramatic speech Tuesday at the World Economic Forum in Davos, Switzerland.

In her address, she called for a public and private sector divestment from fossil fuel companies

"Immediately end all fossil fuel subsidies and immediately and completely divest from fossil fuels. We don't want these things done by 2050, or 2030 or even 2021 — we want this done now," she said.

U.S. Treasury Secretary Steven Mnuchin mocked the teenager on Thursday during a press briefing in Davos.

Keep Reading
The Planet

Even though marathon running is on the decline, half a million people signed up to participate in the 2020 London Marathon. It seems wild that someone would voluntarily sign up to run 26.2 miles, but those half a million people might actually be on to something. A new study published in the Journal of the American College of Cardiology found that running a marathon can help reverse signs of aging.

Researchers at Barts and University College London looked at 138 first-time marathon runners between the ages of 21 and 69. "We wanted to look at novice athletes. We didn't include people who said they ran for more than two hours a week," Dr. Charlotte Manisty, the study's senior author and cardiologist at University College London, said per CNN.

Keep Reading
via David Leavitt / Twitter and RealTargetTori / Twitter

Last Friday, GOOD reported on an infuriating incident that went down at a Massachusetts Target.

A Target manager who's come to be known as "Target Tori," was harassed by Twitter troll David Leavitt for not selling him an $89 Oral-B Pro 5000 toothbrush for a penny.

He describes himself as a "multimedia journalist who has worked for CBS, AXS, Yahoo, and others."

Keep Reading
Communities